Dare Bioscience, Inc. Financing Cash Flow
Dare Bioscience, Inc. (DARE) reported Financing Cash Flow of $235.75 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $951.22K.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$715.47K, a 390.16% decline year-over-year.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $424.13K.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $18.65M, a 4173.22% increase year-over-year.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $19.28M, a 5337.50% increase from fiscal 2024.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $354.52K, a 97.73% decline from fiscal 2023.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $15.64M, a 1064.04% increase from fiscal 2022.
- Dare Bioscience, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.34M, a 98.23% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $951.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $235.75K 10-Q · filed 2026-08-13 | $659.88K derived: sum of 3 quarters · filed 2026-08-13 | $19.31M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$715.47K 10-Q · filed 2026-05-14 | -$291.34K derived: sum of 2 quarters · filed 2026-05-14 | $18.36M derived: sum of 3 quarters · filed 2026-05-14 | $18.32M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $424.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $19.07M derived: sum of 2 quarters · filed 2026-03-26 | $19.03M derived: sum of 3 quarters · filed 2026-08-13 | $19.28M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $18.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $18.61M derived: sum of 2 quarters · filed 2026-08-13 | $18.85M 10-Q · filed 2025-11-13 | $18.64M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$43.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $202.78K 10-Q · filed 2026-08-13 | -$8.54K derived: sum of 3 quarters · filed 2026-08-13 | $427.91K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $246.58K 10-Q · filed 2026-05-14 | $35.26K derived: sum of 2 quarters · filed 2026-05-14 | $471.70K derived: sum of 3 quarters · filed 2026-05-14 | $587.07K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$211.32K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $225.12K derived: sum of 2 quarters · filed 2026-03-26 | $340.49K derived: sum of 3 quarters · filed 2026-03-26 | $354.52K 10-K · filed 2026-03-26 | $433.83K 10-K · filed 2025-03-31 |
| 2024-09-30 | $436.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $551.81K derived: sum of 2 quarters · filed 2025-11-13 | $565.84K 10-Q · filed 2025-11-13 | $5.88M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $115.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $129.40K 10-Q · filed 2025-08-14 | $5.44M derived: sum of 3 quarters · filed 2025-08-14 | $14.01M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $14.03K 10-Q · filed 2025-05-13 | $5.32M derived: sum of 2 quarters · filed 2025-05-13 | $13.90M derived: sum of 3 quarters · filed 2025-05-13 | $14.35M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.89M derived: sum of 2 quarters · filed 2025-03-31 | $14.34M derived: sum of 3 quarters · filed 2025-03-31 | $15.64M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $9.03M derived: sum of 2 quarters · filed 2024-11-14 | $10.33M 10-Q · filed 2024-11-14 | $10.33M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $452.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.75M 10-Q · filed 2024-08-12 | $1.75M derived: sum of 3 quarters · filed 2024-08-12 | $1.76M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-14 | $1.30M derived: sum of 2 quarters · filed 2024-05-14 | $1.30M derived: sum of 3 quarters · filed 2024-05-14 | $2.64M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.46K derived: sum of 2 quarters · filed 2024-03-28 | $1.34M derived: sum of 3 quarters · filed 2024-03-28 | $1.34M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $4.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.34M derived: sum of 2 quarters · filed 2023-11-09 | $1.34M 10-Q · filed 2023-11-09 | $17.35M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.34M 10-Q · filed 2023-08-10 | $17.34M derived: sum of 3 quarters · filed 2023-08-10 | $52.56M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $16.00M derived: sum of 2 quarters · filed 2023-05-11 | $51.22M derived: sum of 3 quarters · filed 2023-05-11 | $64.47M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $51.22M derived: sum of 2 quarters · filed 2023-03-30 | $64.47M derived: sum of 3 quarters · filed 2023-03-30 | $75.85M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $35.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $48.47M derived: sum of 2 quarters · filed 2022-11-10 | $59.84M 10-Q · filed 2022-11-10 | $68.30M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $13.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $24.63M 10-Q · filed 2022-08-09 | $33.08M derived: sum of 3 quarters · filed 2022-08-09 | $38.48M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $11.37M 10-Q · filed 2022-05-12 | $19.83M derived: sum of 2 quarters · filed 2022-05-12 | $25.23M derived: sum of 3 quarters · filed 2022-05-12 | $29.62M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $8.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $13.85M derived: sum of 2 quarters · filed 2022-03-31 | $18.24M derived: sum of 3 quarters · filed 2022-03-31 | $25.13M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.79M derived: sum of 2 quarters · filed 2021-11-10 | $16.68M 10-Q · filed 2021-11-10 | $16.68M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $11.28M 10-Q · filed 2021-08-12 | $11.28M derived: sum of 3 quarters · filed 2021-08-12 | $11.28M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $6.89M 10-Q · filed 2021-05-13 | $6.89M derived: sum of 2 quarters · filed 2021-05-13 | $6.89M derived: sum of 3 quarters · filed 2021-05-13 | $12.04M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | $5.15M derived: sum of 3 quarters · filed 2021-03-30 | $5.15M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $5.15M derived: sum of 2 quarters · filed 2020-11-12 | $5.15M 10-Q · filed 2020-11-12 | $5.15M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $5.15M 10-Q · filed 2020-08-12 | $5.15M derived: sum of 3 quarters · filed 2020-08-12 | $5.07M derived: sum of 4 quarters · filed 2020-08-12 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-14 | -$2.50K derived: sum of 2 quarters · filed 2020-05-14 | -$83.70K derived: sum of 3 quarters · filed 2020-05-14 | -$85.86K derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | -$2.50K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$83.70K derived: sum of 2 quarters · filed 2020-03-27 | -$85.86K derived: sum of 3 quarters · filed 2020-03-27 | $10.11M 10-K · filed 2020-03-27 | |
| 2018-09-30 | -$81.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$83.36K derived: sum of 2 quarters · filed 2019-11-12 | $10.11M 10-Q · filed 2019-11-12 | $10.11M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | -$2.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $10.20M 10-Q · filed 2019-08-14 | $10.20M derived: sum of 3 quarters · filed 2019-08-14 | $10.20M derived: sum of 4 quarters · filed 2019-08-14 | |
| 2018-03-31 | $10.20M 10-Q · filed 2019-05-14 | $10.20M derived: sum of 2 quarters · filed 2019-05-14 | $10.20M derived: sum of 3 quarters · filed 2019-05-14 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $0.00 derived: sum of 2 quarters · filed 2019-04-01 | $155.00K 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $155.00K 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $155.00K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |